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doi:10.1016/j.ijsu.2007.05.010Abstract Background: Postsurgical adhesions severely affect the quality of life of millions of
people worldwide. Numerous attempts have been made to prevent or reduce the incidence of
peritoneal adhesions, but with limited success.
Data sources: An extensive Medline search, textbooks, scientific reports and scientific journals
are the data sources. We also reviewed reference lists in all articles retrieved in the search as
well as those of major texts regarding postsurgical intraperitoneal adhesion formation.
Conclusions: A multifactorial approach including minimizing tissue injury, prophylactic antibi-
otic usage to reduce infectious morbidity, and biochemical agents with or without biomechan-
ical barriers will reduce the amount and severity of adhesions. However, further research is
needed to establish the safety, effectiveness and also the cost/benefit ratio of these sub-
stances in human subjects.
ª 2007 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Abdominal surgery can cause adhesions between tissues
and organs. Approximately 93% of the patients who had
undergone one or more previous surgeries had intra-
abdominal adhesions.1 Postsurgical adhesions are a conse-
quence of injured tissue surfaces (following incision,
cauterization, suturing or other means of trauma) fusing
together to form scar tissue. Recently it was found2 that
all patients who had undergone at least one prior abdomi-
nal surgery developed between one to more than ten adhe-
sions. Postsurgical adhesions severely affect the quality of
life of millions of people worldwide, causing small-bowel312 2912525; fax: þ90 312
m (E. Ergul).
7 Surgical Associates Ltd. Publishobstruction,1 difficult reoperative surgery,3 chronic abdom-
inal and pelvic pain,4 and female infertility.5
Reoperating through a previous wound can be extremely
difficult, risky, and potentially dangerous. Also, adhesiol-
ysis extends operating time, anesthesia, and recovery time
and causes additional risks to the patient such as blood loss,
visceral damage including injury to the bladder, enter-
ocutaneous fistulas, and resection of damaged bowel.6
Numerous attempts have been made to prevent or
reduce the incidence of peritoneal adhesions, but with
limited success.7
History
Intra-abdominal adhesions were described at postmortem
examination of a patient with peritoneal tuberculosis8 in
1836. Some studies suggested in 1849 that coagulated lymphed by Elsevier Ltd. All rights reserved.
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a fatal small bowel obstruction due to intra-abdominal ad-
hesions after an ovarian cyst excision.10 Gibson suggested,
in a thousand patients between 1888 and 1898, that intra-
peritoneal adhesions cause 18 (6%) of the acute intestinal
obstructions.11 Vick suggested, in a retrospective study of
6982 patients admitted to 21 hospitals in Britain during
the period 1925e1930, that strangulated hernias accounted
for half of the total cases, while malignant disease was re-
sponsible for 13% and adhesions accounted for a mere 7%.12
Incidence
In 1930, only 7 (3%) of the acute intestinal obstructions
were caused by adhesions,12 but a study during 1942e1945
of 1252 patients with intestinal obstruction suggested that
31% of the acute intestinal obstructions were caused by
adhesions. Between 1985e1986, McEntee et al. suggested
that in 236 patients with intestinal obstruction, 32% of
the acute intestinal obstructions were caused by adhe-
sions.13 Cox et al. suggested that postoperative adhesions
accounted for 64e79% of admissions with small bowel ob-
struction.14 Adhesions are the most common cause of large
and small intestinal obstructions in the Western world and
account for approximately one third to one half of all intes-
tinal and 60e70% of the small-bowel obstructions.15
Congenital or inflammatory adhesions rarely give rise to
intestinal obstructions, except for malformation.16 How-
ever, between 49 and 74% of the small bowel obstructions
are caused by post surgical adhesions.4,17,18 Small bowel
obstructions from adhesions are responsible for a large pro-
portion of general surgical admissions and unavoidable
operations in current surgical practice. Approximately 1%
of all surgical admissions and 3% of lsaparotomies are the
result of intestinal obstruction due to adhesions.1 In pediat-
ric patients bowel obstruction from adhesions is most prev-
alent; 8% of neonates undergoing abdominal surgery require
a future laparotomy for this complication.19
Structure and function of the peritoneum
The peritoneal cavity encompasses the potential space
defined by the mesothelial serous membrane and extends
superiorly from the diaphragm to the pelvis in its most
caudad extent.20 Anteriorly the peritoneal cavity reflects
onto the posterior aspect of the anterior abdominal muscu-
lature. Posteriorly the peritoneal lining lies superficial to
the retroperitoneal viscera, including the aorta, vena
cava, ureters, and kidneys. The anterior and posterior
peritoneal layers are described collectively as the parietal
peritoneum. The visceral peritoneum represents the meso-
thelial lining cells that are reflected onto the surface of the
viscera, including the stomach, small bowel, spleen, liver,
gallbladder, ovaries, uterus, and portions of the bladder,
colon, and pancreas. The peritoneum covering the intestine
is the serosa of the bowel. The peritoneum also lines the
lesser sac, which communicates with the remainder of
the peritoneal cavity via the epiploic foramen (foramen
of Winslow). In women the peritoneal lining is reflected
onto the fallopian tubes, which communicate through the
open fimbriated ends with the uterus and vagina.20The total area of the peritoneum is approximately
1.8 m2. It is formed by a single layer of mesothelial cells
with an underlying supporting layer of highly vascularized
loose connective tissue.20 Mesothelial cells are organized
into two discrete populations: cuboidal cells and flattened
cells. Gaps (stomata) between neighboring cells of the peri-
toneal mesothelium are found only among cuboidal cells.
Peritonitis increases the width of these stomata. Beneath
the mesothelial cells is a basement membrane of loose col-
lagen fibers, which offers little resistance to diffusion of
molecules smaller than 30 kDa. The basement membrane
overlies a complex connective tissue layer that includes
collagen and other connective tissue proteins, elastic fi-
bers, fibroblasts, adipose cells, endothelial cells, mast
cells, eosinophils, macrophages, and lymphocytes.20
Peritoneal fluid is secreted by the peritoneal serosa and
has the properties of lymph. Diaphragmatic lymphatic
channels provide a means for the entry of peritoneal fluid
(and any bacteria and proinflammatory mediators) through
the thoracic duct into the venous circulation. Inspiration
decreases intrathoracic pressure relative to intra-abdomi-
nal pressure, creating a pressure gradient favoring fluid
movement out of the abdomen.20
Under normal circumstances the peritoneal cavity is
largely a potential space, as only a thin film of fluid
separates the parietal and visceral layers. This fluid layer
serves as a lubricant, allowing the abdominal viscera to
slide freely within the peritoneal cavity. The capacity of
this space is illustrated during peritoneal dialysis, as 2e3 L
of fluid are instilled into the peritoneal cavity without any
patient discomfort.20
Any inflammatory event in the peritoneal cavity results
in local peritoneal irritation with loss of regional mesothe-
lial cells. The defect in the mesothelial lining is repaired by
‘‘metastasis’’ of nearby mesothelial lining cells. Peritoneal
defects heal everywhere simultaneously. A large peritoneal
defect heals in the same amount of time as a small defect,
usually 3e5 days. This process is rapid and usually reconsti-
tutes the peritoneal continuity without adhesion formation.
The origin of the migrating mesothelial cells remains ob-
scure; they may arise from submesothelial stem cells.20Peritoneal healing and adhesion formation
A peritoneal injury invokes an inflammatory response from
the serosal surface with the concurrent loss of the meso-
thelium.21 Increased permeability of the blood vessels in
the traumatized tissues due to the release of PGE2 and his-
tamine produces an outpouring of serosanguineous exu-
dates rich in inflammatory cells. This exudate coagulates
within a period as short as 3 h. Normally, the majority of
fibrinous attachments so formed are lysed within a few
days of development.22 If they persist for 3 days or longer,
fibroblastic proliferation may occur within them, causing
adhesion formation.
Following surgery, the macrophages increase in number
and change function. These postsurgical macrophages are
entirely different from the resident macrophages and
secrete variable substances, including cyclooxygenase
and lipoxygenase metabolites, plasminogen activator, plas-
minogen activator inhibitor (PAI), collagenase, elastase,
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leukotriene B4, prostaglandin E2 etc.
23e25 Postsurgical in-
traperitoneal macrophages recruit new mesothelial cells
onto the surface of the injury. These mesothelial cells later
and in response to cytokines and other macrophage-
secreted mediators form small islands which proliferate
into sheets of mesothelial remesothelialization.17
The organization of the fibrin gel matrix is of major
importance in adhesion formation. This matrix forms in
several steps: from fibrinogen to fibrin monomer, then to
soluble fibrin polymer, and finally, by rinsing tissues with
irrigating solutions (during surgery), becomes insoluble
fibrin polymer. This last product interacts with proteins,
including fibronectin, to form the fibrin gel matrix. This
matrix includes leukocytes, erythrocytes, platelets, endo-
thelium, epithelium, mast cells, and cellular and surgical
debris. Two damaged peritoneal surfaces coming into
apposition while covered with fibrin gel matrix may form
an adhesion, not only at the time of surgical injury, but also
during the next 3e5 days.26,27 Saed and Diamond suggested
that the adhesion fibroblasts develop a specific phenotype
which in part is characterized by the over-expression of
alpha smooth muscle cell actin.28 The over-expression of al-
pha smooth muscle cell actin in adhesion fibroblasts indi-
cates a possible response to peritoneal injury.
Among the earliest factors identified as inducing perito-
neal adhesion formation was ischemia.29 Recent investiga-
tors have found that the production of ischemic tissue is
the most reliable means of inducing adhesion formation
for the evaluation of prophylactic modalities. Induction of
ischemia by coagulation, ligation, or devascularization as
with a free peritoneal graft has all been associated with
the induction of peritoneal adhesions. More recent data
from a number of investigators22,30e34 have established
that the peritoneum which has been made ischemic loses
its spontaneous ability to lyse fibrin. This loss of ability may
take as long as 24 h to occur maximally. Moreover, ischemic
tissue also inhibits fibrinolysis by adjacent normal tissue.22
Weapons of a surgeon to prevent peritoneal
adhesions
Surgical technique
Grafting or suturing peritoneal defects increases ischemia,
devascularization, and necrosis, predisposing the site to
decreased fibrinolytic activity and increased adhesion
formation.35 Ryan et al. also reported that normal saline,
Ringer’s solution, and Medium 199 were equally ineffective
in reducing adhesion formation when fresh blood was drip-
ped intraperitoneally immediately after a wetting proce-
dure.36 Thus, it appears that simply keeping the serosa
moist does not prevent a significant impairment of fibrino-
lytic function. Polubinska et al.37 reported that exposure of
the peritoneal mesothelial cells to 0.9% NaCl, Hanks’,
Earle’s salts solution, or peritoneal dialysis fluid with high
concentration of glucose degradation products results
either in reduction of their viability or in loss of their fibri-
nolytic activity. They also suggested that peritoneal dialysis
fluid with low content of glucose degradation products ap-
pears to be the optimal solution causing the least damageto mesothelial cells and therefore may be the ideal solution
for rinsing the abdominal cavity with low risk of inducing
deterioration of the mesothelial cells’ fibrinolytic activity
and formation of adhesions.37 They postulated that the hy-
pertonic dialysis fluids may be used for rinsing the abdom-
inal cavity.
Foreign bodies have been found in a large percentage of
examined postoperative adhesions.38 Most frequently found
are: surface powders from surgical gloves; lint from packs,
drapes, or gowns; wood fibers from disposable paper items;
and suture materials are also common contaminants. How-
ever, recent data suggest that in the absence of an addi-
tional peritoneal injury foreign bodies are an infrequent
cause of adhesion induction.39e42
Minimizing the production of ischemic tissue remains
a crucial concept. If necessary, reperitonealization should
be performed with a minimal number of sutures which do
not produce significant tension along the suture line. The
use of microsutures may be beneficial, because their low
tensile strength limits the potential for developing ische-
mia.41 The application of free peritoneal or omental grafts
is also contraindicated. Precise hemostasis is necessary to
limit the amount of tissue rendered ischemic by crushing,
ligation, or cautery. The employment of topical hemostatic
agents has not been found to increase the incidence of
postoperative adhesion formation and may on occasion be
advantageous when obtaining hemostasis in areas of gener-
alized oozing.43 Several studies have found that the use of
oxidized cellulose (surgicel) actually decreased subsequent
adhesion formation.44,45 Tingstedt et al. suggested that in-
tra-abdominal administration of different charged polypep-
tides significantly decreased postoperative bleeding and
postoperative adhesions in mice.46 These polypeptides con-
sisted of a combination of positively charged poly-L-lysine
and negatively charged poly-L-glutamate.
Minimal atraumatic handling of tissues is essential for
reducing serosal abrasion and is also recognized to reduce
fibrinolytic activity. Manipulation of tissues with gloved
fingers has been implied by some microsurgeons to be less
traumatic than contact with surgical instruments. However,
electron-microscopic studies indicate that both produce
substantial serosal injury.47
In animal models large clots produced adhesion, but
small clots did not in the absence of the peritoneal injury.48
Hemostasis is essential, and blood should be aspirated in ir-
rigation solution. If pinpoint electrocautery cannot provide
adequate hemostasis, then the smallest gauged synthetic
suture should be used, with special consideration to avoid
tissue strangulation.49
The use of the CO2 laser in gynecologic microsurgery has
also been implied to be beneficial.50,51 Sutton and MacDon-
ald have been reported that laser laparoscopic adhesiolysis
is safe, effective and relatively easy.52
Further studies suggested that compresses, which were
moistened with hot saline (over 45 C), significantly in-
creased intraperitoneal adesions.53 Also, Smith has found
saline warmed to 37 C to be more effective than room-
temperature saline or Hanks’ solution.54
The majority of studies indicate that laparoscopy may
reduce postoperative adhesion formation relative to lapa-
rotomy.55e57 Brokelman et al. found in a randomized trial
that there were no differences in tPA antigen, tPA-activity,
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taken at the beginning compared to samples taken at the
end of the operation. Different intra-abdominal pressures,
light intensities and the choice dissection device did not af-
fect any of the measured parameters. They suggested that
short-term laparoscopy does not affect the peritoneal fibri-
nolytic activity. Intra-abdominal pressure, light intensity
and choice of dissection device do not affect peritoneal ac-
tivity during short-term laparoscopy.57
Prophylactic pharmacological modalities
Non-steroidal anti-inflammatory drugs (NSAIDs)
NSAIDs inhibit prostaglandin and thromboxane synthesis by
changing cyclooxygenase activities. By this inhibition NSAIDs
decrease vascular permeability, plasmin inhibitor, platelet
aggregation, and coagulation and also enhance macrophage
function. NSAIDs modulate a number of aspects of inflam-
mation and have reduced peritoneal adhesion formation in
some animal models.58e60 However, NSAIDS impair wound
healing and increase the risk of bleeding.4,61
Glucocorticoids
Corticosteroid therapy attenuates the inflammatory re-
sponse by reducing vascular permeability and liberation of
cytokines and chemotactic factors. They are administered
intravenously, enterically or intraperitoneally. This therapy
has had mixed results.59 Corticosteroids were studied alone
or with antihistamines.61 Antihistamines inhibit fibroblast
proliferation and are usually used with corticosteroids.
However, corticosteroids have side effects, such as immu-
nosuppression and delayed wound healing.24,59,61
Progesterone/estrogen
Progesterone prevents adhesion formation in animal models
but human studies either failed to confirm this finding or an
increase in adhesion formation was noted when medrox-
yprogesterone acetate was used intramuscularly or intra-
peritoneally.61 Neither estrogen nor gonadotropin-releasing
hormone prevented adhesion formation but fewer adhe-
sions formed than untreated animals.62 It remains unknown
whether a hypoestrogenic state leads to less postsurgical
adhesions in humans.63
Anticoagulants
In animal models, low molecular weight heparin (LMWH)
reduces peritoneal adhesion by increasing the fibrinolysis
due to serine esterase activity.64 Many authors suggested
that LMWH, at standard treatment doses, prevents postsur-
gical intraperitoneal adhesions when administered intra-
operatively either subcutaneously or intraperitoneally.65,66
Fibrinolytics
Fibrinolytic agents caused hemorrhagic complications, al-
though recombinant tPA, when applied locally, reduced
adhesions in animal models without increasing complication
rates.24,48,60 A promising approach in postsurgical adhesion
prophylaxis was described with the use of tPA. The adminis-
tration of recombinant tPA succeeded in reducing adhesion
formation when studied in the rabbit model. The evidence
of further studies suggests that all these approaches have
had only limited success, impeded lack of safety, efficacy,and many adverse effects without eliminating the problem
of postoperative adhesion formation.17,67e70
Antibiotics
Broad-spectrum antibiotics are commonly used for pro-
phylaxis against postoperative infections and adhesion
formation. Less intraperitoneal infection means less in-
traperitoneal adhesion formation. However, intra-abdomi-
nal application causes adhesion formation.60
Vitamin E
Vitamin E theoretically has interesting biological properties
and action for the prevention of peritoneal adhesions. In
vitro studies have shown that vitamin E has antioxidant,
anti-inflammatory, anticoagulant, and antifibroblastic ef-
fects, and decreases collagen production. It has been
successfully used, administered by the oral route, intra-
muscularly and especially intraperitoneally, diluted in olive
oil, in animal models. Vitamin E was found effective for
reducing adhesion formation by some authors.71e73
Methylene blue
Methylene blue is known to inhibit the generation of oxygen
radicals such as superoxide by competing with oxygen for
the transfer of electrons from flavor-enzymes, primarily
xanthine oxidase.74e76 This low molecular weight, partially
liposoluble, vital dye, is also a known inhibitor of guanylate
cyclase. It organizes the smooth muscle relaxation effects
of nitric oxide, blocking its activation by blocking NO bind-
ing sites of guanylate cyclase.77,78 In recent studies, it has
been suggested that intraperitoneal application of methy-
lene blue can be used as an effective agent in the preven-
tion of postoperative adhesions.79e81 Dinc et al. suggested
that methylene blue prevents peritoneal adhesions but
causes a significant impairment of anastomotic bursting
pressure during the early phase of the wound healing pro-
cess by its transient inhibitory effect on the nitric oxide
pathway.82
Pentoxifylline
Pentoxifylline, a methyl xanthine derivate, enhances
plasma fibrinolytic activity, reduces plasma fibrinogen
levels, inhibits platelet aggregation and increases ery-
throcyte and leukocyte flexibility.83e85 Tarhan et al.
suggested that pentoxifylline prevents postoperative intra-
abdominal adhesions either by intraperitoneal or intrave-
nous administration.86
3-Hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors (HMG-CoA-I)
Either Lovastatin or Atorvastatin increases tPA and de-
creases PAI-1 in human mesothelial cell incubation.87
Aarons et al. suggested that Lovastatin and Atorvastatin re-
duced adhesion formation by 26% and 58%, respectively,
without affecting anastomotic burst pressure, intraperito-
neal administration in rats.87Adjuvant barrier therapy
The ideal barrier, besides being safe and effective, should
be non-inflammatory, non-immunogenic, persist during the
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sutures or staples, remain active in the presence of blood
and be completely biodegradable. Also, it should not
interfere with healing, promote infection, or cause
adhesions.27
Barrier solutions
Adept (Shire GmbH and Co. KG) is a 4% icodextrin solution
(a-1,4-linked dextrin polymer of glucose) and reduces the
extent and severity of adhesion formation in animal
models.88e93 It has also been used widely as a peritoneal
dialysis solution for several years. Adept is a non-viscous
adhesion barrier applied intra-abdominally after surgery.
The presence of the polymer creates a constant fluid layer
between peritoneal surfaces and acts to reduce adhesion
formation by inducing hydroflotation throughout the ab-
dominal cavity for several days. It is reabsorbed gradually
through the lymphatic system.94
Hyalobarrier (Baxter GmbH) is a tissue precoating
solution and forms a selective barrier made of purified
autocrosslinked hyaluronan with increased density, viscos-
ity, and adhesive properties. It remains intra-abdominally
for 3e7 days.95,96 It provides lubrication and gliding effects.
After surgical trauma, the peritoneal area affected (ap-
proximately 25  15 mm) was covered to a depth of 3 mm
by expelling successive trails of the gel out of the syringe
across the surface.97 Martin-Cartes et al. suggested that hy-
aluronidase gel was moderately superior to obtain reduc-
tion of consistency of the adhesion with fibrin glue.98
Hyaluronidase gel also has the advantage of being
inexpensive.
Phospholipids in the form of phosphoric acid diesters
were defined as a surfactant-like substance in effluent
peritoneal dialysis fluid, and possess good release and lubri-
cating properties.99 Experimental results in rat studies with
peritoneal instillation of phosphatidylcholine upon abdomi-
nal closure seemed to reduce adhesion formation.100e103
It may reduce the risk of adhesion development by diminish-
ing fibrin formation between peritoneal surfaces and
defects.59
Solid barriers
Experimental studies have demonstrated that covering
lesions of the parietal peritoneum with microsurgically
applied autologous peritoneal transplants can completely
prevent severe adhesion formation.27 The advantage of
a synthetic barrier is that the material does not need to
be obtained surgically and can be cut to size outside of
the abdomen and then applied without sutures.104
Carboxymethylcellulose is a derivative of cellulose.
Carboxymethylation of the glucosidic hydroxyl groups
makes the polymer hydrophilic. It is negatively charged at
physiological pH and freely soluble. It is spontaneously
broken down.63,105 It has heavy molecular weight and slow
peritoneal absorption.65 Nevertheless, it cannot completely
eliminate postoperative adhesions in all cases.106,107 Me-
diana et al. suggested that while carboxymethylcellulose
film has been shown to decrease adhesions in other models,
healing of a rabbit colonic anastomosis even in the pres-
ence of an anastomotic defect takes place, further suggest-
ing that the stimulus for adhesion formation can overcome
the antiadhesion properties of carboxymethylcellulose.108Interceed TC7 is made of oxidized regenerated cellu-
lose. It is already in routine clinical use as a ‘‘first genera-
tion’’ adhesion barrier.89,109e112 As a mesh like product, it
rapidly forms a soft gelatinous mass that provides a protec-
tive coating around healing tissue during the first 7e10 days
after application.113e115 It is absorbed in the abdominal
cavity within 2 weeks.93
Polytetrafluoroethylene (PTFE) is a non-reactive, anti-
thrombogenic, non-toxic synthetic fabric with small pores
that inhibit cellular transmigration and tissue adherence.
A PTFE barrier prevents adhesion formation and reforma-
tion regardless of the type of tissue injury or whether
hemostasis is achieved.27 It was found that expanded PTFE
was associated with fewer postsurgical adhesions to the
sidewall than oxidized regenerated cellulose.116
TachoComb H is a tissue glue-coated collagen sponge.
A statistically significant reduction in all adhesion score cri-
teria was found by Schneider et al. in an animal model.117
Poly-DL-lactide (PDLA) is an absorbable copolymer sys-
tem which has not been formally investigated as a barrier
agent for peritoneal adhesions. Wallwiener et al. suggested
that PDLA was significantly more effective in preventing
adhesions than Ringer’s lactate sollution.93
Gene therapy
Hepatocyte growth factor (HGF), also known as scatter
factor, exerts multiple effects on a variety of cells, in-
cluding mesothelial cells. It can stimulate the proliferation
and migration of mesothelial cells, inhibit collagen de-
position and has a fibrinolytic capacity.118e120 Liu et al.
demonstrated that local application of recombinant adeno-
virus carrying the HGF gene reduces adhesion formation in
rat model.121Conclusion
Strategies to reduce adhesion formation include improving
surgical techniques, optimizing laparoscopy conditions,
using pharmacologic interventions targeted at the inflam-
matory response and/or fibrin deposition, and using agents
that provide a physical barrier to adhesion formation. While
these strategies have provided some success, none have yet
proved totally successful in abolishing adhesions. Further
research to ensure that adhesion prevention is optimal is
therefore essential.
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